Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation

BACKGROUND: Recombinant human erythropoietin (EPO) is the leading biotechnology engineered hormone for treatment of anaemia associated with chronic conditions including kidney failure and cancer. The finding of EPO receptors on cancer cells has raised the concern that in addition to its action in er...

Descripción completa

Detalles Bibliográficos
Autores principales: Inbar, D, Cohen-Armon, M, Neumann, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494439/
https://www.ncbi.nlm.nih.gov/pubmed/22955851
http://dx.doi.org/10.1038/bjc.2012.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494439/
https://www.ncbi.nlm.nih.gov/pubmed/22955851
http://dx.doi.org/10.1038/bjc.2012.395

Ejemplares similares